<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        6-626-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        JURNISTA 16 mg prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HYDROMORPHONE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        245.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Alza Corporation" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Alza Corporation
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            JANSSEN-CILAG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N02AA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>JURNISTA contains the active substance <em>hydromorphone hydrochloride</em>. It belongs to a group of medicines called &lsquo;opioid analgesics&rsquo; (morphine-related painkillers).&nbsp;</p><p>&nbsp;</p><p>JURNISTA is used to treat moderate to severe pain in adults who require continuous pain relief.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t take JURNISTA:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you&rsquo;re allergic to hydromorphone hydrochloride or any of the other ingredients of this medicine (listed in section 6).&nbsp; See &lsquo;Look out for serious side effects&rsquo; in section 4, for signs of an allergic reaction.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you&rsquo;ve been diagnosed with serious narrowing or blockage of the stomach and/or intestine (bowel)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you&rsquo;ve had surgery which may have left you with &lsquo;blind loops&rsquo; in your intestine  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat acute pain, or pain after surgery</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe acute asthma.</p><p>Tell your doctor if any of these applies to you.&nbsp;</p><p>&nbsp;</p><p><strong>JURNISTA must not be given to </strong>children below age 18, or to women who are pregnant, in labor or during delivery.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking JURNISTA. Some people need to be especially careful when they&rsquo;re taking this medicine.</p><p>&nbsp;</p><p>Serious side effects</p><p>JURNISTA can cause serious side effects, including breathing difficulties and allergic reactions. You must be aware of these side effects, or look out for certain signs of illness while you are taking JURNISTA. See &lsquo;Look out for serious side effects&rsquo; in section 4.</p><p>&nbsp;</p><p><strong>Check with your doctor</strong> if you have, or have recently had, any of the following:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing or problems with your lungs<strong>,</strong> including chronic obstructive pulmonary disease (COPD)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment with other morphine-related painkillers<strong> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headaches or a head injury<strong> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic constipation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden onset of severe diarrhea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any disease of your intestine, including obstruction or inflammatory bowel disease (IBD)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pancreatitis (inflammation of the pancreas) or disease of the bile duct&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with your kidneys, liver, heart or adrenal gland</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an underactive thyroid (hypothyroidism)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an enlarged prostate</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty passing urine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an addiction to alcohol or drugs; or if you&rsquo;ve had a severe reaction to stopping alcohol (sometimes called delirium tremens)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; central nervous system (CNS) depression &ndash; signs of this include severe drowsiness, low body temperature and sometimes coma&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits or seizures (epilepsy or convulsions)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; toxic psychosis (extreme confusion)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kyphoscoliosis (abnormal curvature of the spine).</p><p>&nbsp;</p><p><strong>Tell your doctor</strong>:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are going to have a chordotomy or similar<strong> </strong>surgery to relieve your pain. You should not take JURNISTA shortly before or shortly after the operation, so your doctor will tell you when to stop taking JURNISTA and when you can start taking it again, or if your dose needs to be changed.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are older than 60 years of age. You may be more likely to experience side effects, so your doctor may give you a low starting dose.</p><p>&nbsp;</p><p>Constipation</p><p>Constipation (not enough or hard bowel movements) is a common side effect of drugs like JURNISTA and is unlikely to go away without treatment. Talk to your doctor or pharmacist about the use of laxatives (medicines to treat constipation) and stool softeners to prevent or treat constipation while taking JURNISTA.</p><p><strong>&nbsp;</strong></p><p>When you go to the toilet</p><p>You may notice what looks like your JURNISTA tablet in your stools. Don&rsquo;t worry &ndash; this is simply the tablet shell, which passes through your body unchanged. It doesn&rsquo;t mean the tablet isn&rsquo;t working.</p><p>&nbsp;</p><p>Other medicines and JURNISTA</p><p>Some medicines can affect the way JURNISTA works, or make it more likely that you&rsquo;ll have side effects.</p><p><strong>&nbsp;</strong></p><p><strong>Don&rsquo;t take JURNISTA </strong>if you&rsquo;re taking:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antidepressants called monoamine oxidase inhibitors (MAOIs), or have taken them within the last 14 days</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other morphine-related painkillers (buprenorphine, nalbuphine or pentazocine).&nbsp; Tell your doctor if any of these applies to you.</p><p><strong>&nbsp;</strong></p><p><strong>Check with your doctor</strong> before taking JURNISTA if you&rsquo;re taking:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any medicine which makes you sleepy or drowsy (such as sleeping pills or tranquillisers)  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle relaxants (these may be prescribed for back pain).</p><p><strong>&nbsp;</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.&nbsp;</p><p>&nbsp;</p><p>JURNISTA with alcohol</p><p>Drinking alcohol whilst taking JURNISTA may make you feel more sleepy or increase the risk of serious side effects, such as shallow breathing, with a risk of stopping breathing and loss of consciousness. It is recommended not to drink alcohol while you&rsquo;re taking JURNISTA.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>JURNISTA is not recommended for use during pregnancy. Talk to your doctor<strong> </strong>if you&rsquo;re pregnant, think you may be pregnant or are planning to have a baby.</p><p><strong>&nbsp;</strong></p><p><strong>Don&rsquo;t take JURNISTA </strong>if you&rsquo;re breast feeding, because the active substance can pass into breast milk.</p><p>&nbsp;</p><p>Driving and using machines&nbsp;</p><p>JURNISTA can make you drowsy.&nbsp; Don&rsquo;t drive, operate machines or do hazardous work until you&rsquo;re sure you&rsquo;re not affected. Take special care if your dose or type of medicine is changed.</p><p><strong>&nbsp;</strong></p><p>JURNISTA extended-release tablets contains lactose&nbsp;&nbsp;</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p>JURNISTA extended-release tablets may contain sodium metabisulfite&nbsp;&nbsp;</p><p>This may cause an allergic reaction or a severe asthma attack, especially in people with asthma. See &lsquo;Look out for serious side effects&rsquo; in section 4, for signs of an allergic reaction.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.&nbsp;&nbsp;</p><p>&nbsp;</p><p>If you are not routinely taking a morphine-related painkiller, the usual starting dose of JURNISTA is up to 8 mg each day. If you&rsquo;re changing from a different morphine-related painkiller, your doctor may prescribe a different starting dose of JURNISTA.</p><p>&nbsp;</p><p>Your doctor may increase the dose until your pain is controlled, leaving a gap of at least three days between dose increases (for example, if your first dose is on a Monday, the earliest the dose could be increased is Thursday).</p><p>&nbsp;</p><p>Taking your daily tablet</p><p><strong>Swallow your JURNISTA tablet whole, with a glass of water.&nbsp; </strong></p><p>JURNISTA tablets are &lsquo;extended-release&rsquo;, which means that the active substance is gradually released into the body after taking the tablet.&nbsp;</p><p>Don&rsquo;t chew, break or crush JURNISTA tablets &ndash; if you do, there&rsquo;s a danger you could overdose, because the medicine will be released into your body too quickly.</p><p>Don&rsquo;t crush and inject the tablets, as some of the ingredients could potentially cause death if taken this way.</p><p>&nbsp;</p><p>Try to take your JURNISTA tablet at the same time each day. You can take this medicine with or without food.</p><p>&nbsp;</p><p>If you take more JURNISTA than you should</p><p><strong>Contact your doctor or the nearest hospital emergency department immediately</strong>. If possible, tell them what tablets have been taken, and how many.</p><p>&nbsp;</p><p>If you&rsquo;ve taken an overdose, you may feel very drowsy, and have difficulty breathing. The effects of an overdose can get worse &ndash; they include clammy skin, small pupils, low blood pressure and coma (unconsciousness). Someone who&rsquo;s taken a serious overdose may stop breathing, have a heart attack and die.</p><p>&nbsp;</p><p>If you forget to take JURNISTA</p><p>Take the next dose as soon as you remember, and then at the same time each day.<strong> Don&rsquo;t take extra tablets or a double dose to make up for forgotten tablets.</strong> Contact your doctor or pharmacist if you are not sure what to do.</p><p>&nbsp;</p><p>If you stop taking JURNISTA</p><p>When it&rsquo;s time for you to stop taking JURNISTA, your doctor will reduce your dose gradually &ndash; usually by halving the dose every two days. Once you&rsquo;ve reached the lowest possible dose, your doctor will discuss with you when you can stop taking JURNISTA.&nbsp;</p><p>&nbsp;</p><p>Some people get withdrawal symptoms<strong> </strong>when the JURNISTA dose is suddenly reduced, or if treatment is suddenly stopped. These symptoms include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety or irritability  large (dilated) pupils</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blushing or sweating&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; crying for no reason&nbsp;</p><p>&nbsp;</p><p>nausea, vomiting or diarrhea stomach pains or joint pain.</p><p>Tell your doctor if you get any of these symptoms after you stop taking JURNISTA or if the JURNISTA dose is reduced.&nbsp;</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Look out for serious side effects</p><p><strong>Breathing difficulties &ndash; </strong>slow or shallow breathing (respiratory depression) is uncommon in people taking JURNISTA (may affect up to 1 in 100 people).&nbsp; This is more likely to affect certain groups of people, such as the elderly or the very weak.&nbsp; If your breathing becomes very slow or shallow, and you feel extremely sleepy:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; keep moving and talking as much as possible</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; contact your doctor or get emergency medical help straight away.</p><p>Talk to your doctor about medicines that can be used to treat respiratory depression.&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Allergic reactions</strong> &ndash; these are very rare in people taking JURNISTA (may affect up to 1 in 10000 people). The signs include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, mouth, tongue or throat, which may cause difficulty swallowing or breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy rash.</p><p>Contact your doctor or get emergency medical help straight away if you notice any of these signs.&nbsp; Your doctor may decide that JURNISTA is not suitable for you.</p><p>&nbsp;</p><p><strong>Allergic reactions</strong> &ndash; these are uncommon in people taking JURNISTA (may affect up to 1 in 100 people). The signs include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, mouth, tongue or throat, which may cause difficulty swallowing or breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy rash.</p><p>Contact your doctor or get emergency medical help straight away if you notice any of these signs.&nbsp; Your doctor may decide that JURNISTA is not suitable for you.</p><p>&nbsp;</p><p>Other side effects Very common side effects (may affect more than 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation; nausea; vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sleepy, weak or dizzy; headache.</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea; stomach pains; inflammation of the stomach and intestines</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion; worsening of reflux of food into the throat (heartburn); dry mouth</p><p>dehydration; decreased appetite; weight loss</p><p>seeing or hearing things that are not there (hallucinations)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused, anxious, nervous or restless</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new or worsening depression; mood changes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling drowsy; trouble sleeping (insomnia); abnormal dreams</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; forgetfulness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle tremors or spasms; tingling or numbness of the skin; decreased sense of touch or sensation, especially in the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision; spinning sensation (vertigo)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating; itching; skin rash or flushing&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, such as joint, muscle, back or limb pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain when urinating</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; craving following medicine withdrawal</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling due to fluid retention</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever or chills; feeling of discomfort of the chest</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; falls; bruises.</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing (wheezing), which may be due to narrowing of the airways in the lungs  &nbsp;&nbsp; runny nose</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation or blockage of the bowel; pockets in the inner wall of the colon; haemorrhoids</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes to bowel movements, such as alternating between constipation and diarrhea; abnormal stools, such as blood in the stools; bloating; passing wind; belching or burping</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty swallowing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluid retention</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; panic attacks; feeling paranoid, listless, uneasy or tense; crying</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of extreme happiness (euphoria)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low sex drive</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep problems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; brain disorders (encephalopathy)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased alertness or awareness; difficulty concentrating; difficulty forming or speaking words</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling faint or fainting; lack of coordination; balance problems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable twitching, jerking or writhing movements; sudden jerking of muscles; increased sense of touch or sensation, especially in the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in taste sensation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double vision; dry eyes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears (tinnitus)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in heart beat, such as skipped, fast or irregular heart beats (palpitations)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urination problems, such as inability to urinate, difficulty starting to urinate or increased frequency of urination</p><p>problems having sex or impotence</p><p>flu-like symptoms, such as feeling hot or cold</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems walking</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling jittery, abnormal or generally unwell</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; overdose of the medicine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased level of oxygen in the blood; decreased level of potassium in the blood; increased level of liver enzymes in the blood.</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast or deep breathing (hyperventilation); sneezing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; perforation of the bowel; loss of contractions in the bowel wall; inflammation of the duodenum; tears in the anus</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired stomach emptying; retention of the tablet shell in the stomach so it fails to pass through the bowel; painful passing of stools</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aggression</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits or seizures</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; restlessness or hyperactivity; exaggerated or increased reflexes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in thinking, remembering information, or solving problems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; small pupils</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow heart beat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burning sensation of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling drunk or hangover feeling</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased body temperature</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of the enzyme &lsquo;amylase&rsquo; in the blood</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased uric acid levels in the blood, which may cause gout</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased levels of sex hormones, such as decreased testosterone level in the blood.</p><p>&nbsp;</p><p>If you get side effects, talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not take JURNISTA after the expiry date on the pack.</p><p>&nbsp;</p><p>If you have any unwanted JURNISTA tablets, don&rsquo;t dispose of them in your waste water or household rubbish.&nbsp; Ask your pharmacist how to dispose of medicines no longer required.&nbsp; This will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What JURNISTA contains</p><p><em>&nbsp;</em></p><p>&nbsp;</p><p>The active substance is hydromorphone hydrochloride. JURNISTA tablets come in different strengths.</p><p><strong>&nbsp;</strong></p><p>Each 8 mg tablet contains 8.72 mg and delivers 8 mg hydromorphone hydrochloride, equivalent to 7.12 mg hydromorphone.</p><p>Each 16 mg tablet contains 16.35 mg and delivers 16 mg hydromorphone hydrochloride, equivalent to 14.24 mg of hydromorphone.</p><p>Each 32 mg tablet contains and delivers 32 mg hydromorphone hydrochloride, equivalent to 28.48 mg of hydromorphone.</p><p>Each 64 mg tablet contains and delivers 64 mg hydromorphone hydrochloride, equivalent to 56.96 mg of hydromorphone.</p><p>&nbsp;</p><p>The other ingredients are:&nbsp;</p><p>Butyl hydroxytoluene E321, cellulose acetate, glycerol triacetate, iron oxide black E172, hypromellose, lactose, macrogol, magnesium stearate, polyethylene oxide, povidone, propylene glycol, sodium chloride, titanium dioxide E171</p><p>&nbsp;</p><p>The 8 mg tablet also contains ferric oxide red E172.</p><p>The 16 mg and 32 mg tablets also contain ferric oxide yellow E172. The 64 mg tablets also contain indigo carmine lake E132.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The 8 mg tablets are red, round and printed with ‘HM 8’ in black ink on one side. 
The 16 mg tablets are yellow, round and printed with ‘HM 16’ in black ink on one side. 
The 32 mg tablets are white, round and printed with ‘HM 32’ in black ink on one side. The 64 mg tablets are blue, round and printed with ‘HM 64’ in black ink on one side. 
 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>not mentoned</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dec 2012
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي جورنيستا على المادة الفعالة ھيدرومورفون ھيدروكلوريد. وھو ينتمي إلى فئة من الأدوية تُسمى &quot;المسكنات أفيونية المفعول&quot; (مسكنات الألم ذات الصلة بالمورفين).&nbsp;</p><p><strong>&nbsp; </strong></p><p dir="RTL">يسُتخدم جورنيستا في علاج الألم المتوسط إلى العنيف في البالغين الذين يحتاجون تسكيناً مستمراً للألم.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>جورنيستا</strong><strong> </strong>&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط الحساسية تجاه مادة ھيدرومورفون ھيدروكلوريد أو أي &nbsp;من المكونات الأخرى في ھذا الدواء (مذكورة في القسم 6). انظر &quot; احذر الآثار الجانبية الخطيرة&quot; في الٍقسم 4، لعلامات رد فعل تحسسي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُشخَصا ً بضيق المعدة الخطير أو انسدادھا و/أو الأمعاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أجريت جراحة تركتك مصابا ً ب &quot;عروة مُقفلة&quot; بأمعائك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج الألم الحاد أو الألم بعد الجراحة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني الربو الحاد العنيف.&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كان أي من ذلك ينطبق عليك.&nbsp;</p><p><strong>&nbsp; </strong></p><p dir="RTL">لا يجب إعطاء جورنيستا إلى الأطفال الأصغر من 18، أو السيدات الحوامل، أو في المخاض أو أثناء الولادة.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات&nbsp; </strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول جورنيستا، يحتاج بعض الناس للحذر عند تناولھم ھذا الدواء.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية خطيرة&nbsp; </strong></p><p dir="RTL">يمكن أن يسبب الدواء جورنيستا آثاراً جانبية خطيرة، تتضمن صعوبات التنفس، وردود الفعل التحسسية.&nbsp;</p><p dir="RTL">يجب أن تكون على دراية بھذه الآثار الجانبية، أو احذر علامات معينة للمرض بينما تتناول جورنيستا. انظر &quot;احذر عن الآثار الجانبية الخطيرة&quot; في القسم 4.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>استشر طبيبك</strong> إذا كنت مصاباً، أو إذا سبقت لك الإصابة مؤخرا ً بأي&nbsp; من التالي:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس أو مشكلات برئتيك، بما في ذلك الداء الرئوي الِمُسِد المزمن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج باستخدام مسكنات ألم أخرى ذات صلة بالمورفين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات صداع أو إصابة بالرأس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك مزمن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بداية مفاجئة لإسھال شديد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي أمراض بأمعائك، بما في ذلك الانسداد أو داء الأمعاء الالتھابي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتھاب البنكرياسي (التھاب البنكرياس) أو مرض القناة الصفراوية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في كليتيك، أو كبدك، أو قلبك، أو الغدة الكظرية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف نشاط الغدة الدرقية (القصور الدرقي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم البروستاتا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التبول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إدمان الكحول أو المخدرات، أو إذا أصُبت برد فعل عنيف تجاه الإقلاع عن الكحول (يُسمى أحيانا ً بالھذيان الارتعاشي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خمود الجھاز العصبي المركزي &ndash; وتتضمن العلامات الدالة على ذلك الدوخة الشديدة، وانخفاض حرارة الجسم وأحيانا ً الغيبوبة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات صرعية أو تشنجية (صرع أو تشنجات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ذُھان سُمّي (الارتباك البالغ)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجَنَف الحُدابي (الانحناء غير الطبيعي للعمود الفقري)</p><p>&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك:&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستجري بضعا ً للحبل أو جراحة شبيھة لتسكين الألم، يجب ألّا&nbsp; تستخدم جورنيستا قبل أو بعد فترة وجيزة من العملية، ولذلك سيخبرك طبيبك متى عليك إيقاف تناول جورنيستا، ومتى يمكنك بدء استخدامه ثانيةً، أو ما إذا كانت جرعتك تحتاج للتعديل.<strong> </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أكبر من 60 عاما ً من العمر، فيمكن أن تكون أكثر عُرضة للمعاناة من الآثار الجانبية، لذلك قد يعطيك طبيبك جرعات مبدئية منخفضة.<strong> </strong></p><p dir="RTL">&nbsp; <strong>الإمساك&nbsp; </strong></p><p dir="RTL">الإمساك (التبرز بشكل غير كافي أو التبرز الصعب) أثر جانبي شائع للأدوية الشبيھة بدواء جورنيستا، ومن غير المحتمل أن يختفي دون علاج، تحدث مع طبيبك أو الصيدلي بخصوص استخدام المُلينات (أدوية علاج الإمساك) ومرققات البراز لمنع أو لعلاج الإمساك أثناء تناول جورنيستا.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>عند الذھاب إلى المرحاض&nbsp; </strong></p><p dir="RTL">قد تُلاحظ ما يشبه قرص جورنيستا في برازك، لا تقلق، ھذا ببساطة غلاف القرص الذي يمر عبر الجسم دون تغير، ولا يعني ذلك أن القرص لا يعمل.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>أدوية أخرى بالتزامن مع جورنيستا&nbsp; </strong>يمكن لبعض الأدوية أن تؤثر على طريقة عمل جورنيستا، أو قد تجعله أكثر عرضة للتسبب في آثار جانبية.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>لا تتناول جورنيستا </strong>إذا كنت تتناول أي من الأدوية التالية:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب المسماة مثبطات الأكسيداز أحادي الأمين، أو إذا كنت قد استخدمتھم خلال الأربعة عشر يوما ً الأخيرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسكنات الألم الأخرى ذات الصلة بالمورفين (بابرينورفين، نالبوفين، أو بينتازوسين).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كان أي من ذلك ينطبق عليك.&nbsp;</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>استشر طبيبك </strong>قبل تناول جورنيستا إذا كنت تتناول:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي أدوية تصيبك بالنعاس أو الدوخة (كأقراص المنوّمات، أو المھدئات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُرخيات العضلات (يمكن وصفھا لعلاج ألم الظھر).</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدليالصيدلي إذا كنت تتناول، أو إذا كنت قد تناولت مؤخراً، أو قد تتناول أي أدوية أخرى.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>جورنيستا</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الكحول</strong><strong> </strong>&nbsp;&nbsp;</p><p dir="RTL">شرب الكحول أثناء تناول جورنيستا قد يجعلك أكثر نعاساً أو يجعلك أكثر عرضة للآثار الجانبية الخطيرة كالتنفس الضحل، مع العُرضة لتوقف التنفس وفقد الوعي، ويُوصى بعدم شُرب الكحول أثناء تناول جورنيستا.&nbsp;</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong><strong> </strong>&nbsp;&nbsp;</p><p dir="RTL">يوصى بعدم استخدام جورنيستا أثناء الحمل، أخبري طبيبكِ&nbsp; إذا كنتِ&nbsp; حاملاً، أو تشكين أنك حامل، أو تخططين للحمل.&nbsp;</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>لا تتناولي جورنيستا</strong> إذا كنتِ&nbsp; تُرضعين رضاعة طبيعية، لأن المادة الفعالة قد تمر إلى لبن الثدي.&nbsp;</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>قيادة</strong><strong> </strong><strong>المركبات</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong><strong> </strong>&nbsp;&nbsp;</p><p dir="RTL">يمكن لدواء جورنيستا أن يسبب لك الدوخة، لا تقم بالقيادة أو استخدام الآلات، أو أي عمل خطر حتى تتأكد من عدم تأثرك، كن حذرا ً بشكل خاص إذا تغيرت جرعة دوائك أو نوعه.&nbsp;</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>تحتوي أقراص جورنيستا ممتدة الإطلاق على لاكتوز</strong>&nbsp;</p><p dir="RTL">إذا كان الطبيب قد أخبرك أنك لا تتحمل بعض أنواع السكر، فاتصل بطبيبك قبل تناول ھذا الدواء.&nbsp;&nbsp;</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>قد تحتوي أقراص جورنيستا ممتدة الإطلاق على بيروكبريتيت الصوديوم&nbsp; </strong></p><p dir="RTL">قد يسبب ذلك رد فعل تحسسي أو نوبة ربو عنيفة، خاصة في الأشخاص المصابون بالربو، انظر &quot; ابحث عن&nbsp; الآثار الجانبية الخطيرة&quot; في القسم 4، لعلامات رد فعل تحسسي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول ھذا الدواء حسب إرشادات الطبيب أو الصيدلي تماماً، استشر الطبيب أو الصيدلي في حالة عدم التأكد من كيفية الاستخدام.&nbsp;&nbsp; <strong>&nbsp;&nbsp;</strong></p><p dir="RTL">إذا لم تكن تتناول مسكن ألم ذا صلة بالمورفين بشكل روتيني، فإن الجرعة المبدئية من جورنيستا حتى 8 ملجم يومياً، إذا كنت تنتقل من مسكن آخر ذي صلة بالمورفين، فقد يصف لك طبيبك جرعة مبدئية مختلفة من جورنيستا.&nbsp;</p><p>&nbsp;</p><p dir="RTL">قد يزيد طبيبك الجرعة حتى يتحكم في الألم، تاركاً فاصلاً زمنياً من ثلاثة أيام بين زيادات الجرعة (على سبيل المثال، إذا كانت الجرعة يوم الاثنين، فإن الزيادة الأقرب للجرعة ستكون يوم الخميس).&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>تناول قرصك اليومي&nbsp; </strong></p><p dir="RTL"><strong>ابلع قرصك من دواء جورنيستا كاملاً، مع زجاجة ماء.&nbsp; </strong></p><p dir="RTL">أقراص جورنيستا &quot;ممتدة الإطلاق&quot;، ويعني ذلك أن المادة الفعالة تنطلق بالتدريج إلى الجسم بعد تناول القرص.&nbsp;</p><p dir="RTL">لا تبلع أقراص جورنيستا أو تكسرھا أو تھشمھا، إذا فعلت ذلك، يمكن أن تتعرض لفرط الجرعة، لأن الدواء سيتم إطلاقه إلى جسم بسرعة بالغة.&nbsp;</p><p dir="RTL">لا تھشم وتحقن الأقراص، حيث أن بعض المكونات قد تسبب الوفاة عند تناولھا بھذه الطريقة.&nbsp;</p><p>&nbsp;</p><p dir="RTL">حاول تناول جورنيستا في نفس الموعد يومياً، يمكنك تناول ھذا الدواء مع الطعام أو بدونه.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>في</strong><strong> </strong><strong>حالة</strong><strong> </strong><strong>تناولك</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>زائدة عن اللازم</strong><strong> </strong><strong>من</strong><strong> </strong><strong>جورنيستا</strong><strong> </strong>&nbsp;&nbsp;</p><p dir="RTL"><strong>اتصل بطبيبك أو بقسم الطوارئ بأقرب مستشفى فوراً، </strong>وأخبرھم إن أمكن عن نوع الأقراص التي تناولتھا وكميتھا.&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا كنت قد تناولت جرعة مفرطة، قد تشعر بالدوخة، وقد تعاني صعوبة التنفس، ويمكن أن تسوء تأثيرات الجرعة المفرطة، بما في ذلك رطوبة الجلد، صغر البؤبؤين، انخفاض ضغط الدم، والغيبوبة (فقد الوعي)، وقد يتوقف تنفس المريض الذي تناول جرعة مفرطة خطيرة، وقد يتعرض لنوبة قلبية ويتوفى.&nbsp;</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>في</strong><strong> </strong><strong>حالة</strong><strong> </strong><strong>نسيان</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>جورنيستا</strong><strong> </strong>&nbsp;&nbsp;</p><p dir="RTL">تناول الجرعة التالية حال تذكرھا على الفور. ثم في نفس الموعد يومياً، <strong>لا</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>أقراصاً إضافية أو جرعة</strong><strong> </strong><strong>مزدوجة</strong><strong> </strong><strong>لتعويض</strong><strong> </strong><strong>الجرعة</strong><strong> </strong><strong>الفائتة، </strong>ومتى وصلت لأقل جرعة ممكنة، سيناقشك الطبيب في كيفية إيقاف تناولك جورنيستا.&nbsp;</p><p>&nbsp;</p><p dir="RTL">يصاب بعض الأشخاص بأعراض انسحاب عند تقليل جرعة جورنيستا فجأة، أو عند إيقاف العلاج فجأة، وتتضمن تلك الأعراض:&nbsp;</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق أو التھيج العصبي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كِبر (اتساع) البؤبؤين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورد الوجه أو التعرق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البكاء دون سبب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان، القيء أو الإسھال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة أو المفاصل</p><p dir="RTL">أخبر طبيبك إذا أصُبت بأي من ھذه الأعراض بعد إيقاف تناولك جورنيستا، أو عند تقليل جرعة جورنيستا.&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك المزيد من الأسئلة بخصوص ھذا الدواء، اسأل طبيبك أو الصيدلي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب ھذا الدواء آثارًا جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>احذر الآثار الجانبية الخطيرة&nbsp; </strong></p><p dir="RTL"><strong>صعوبات التنفس </strong>&ndash; التنفس البطيء أو الضحل (الخمود التنفسي) غير شائع في الأشخاص الذين يتناولون جورنيستا (قد يؤثر على مريض واحد من كل 100 مريض)، ومن المرجح أن يؤثر على مجموعات معينة من الأشخاص، كالمسنين أو بالغي الضعف، إذا أصبح تنفسك بطيئا ً أو ضحلاً، وإذا كنت تشعر بالنعاس البالغ:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داوم على الحركة والحديث بقدر الإمكان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بطبيبك أو احصل على المعونة الطبية الطارئ فورا ً.</p><p>&nbsp;</p><p dir="RTL">تحدث مع طبيبك بخصوص الأدوية التي يمكن استخدامھا لعلاج الخمود التنفسي.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>ردود فعل تحسسية</strong> &ndash; وھي نادرة جداً في الأشخاص الذين يتناولون جورنيستا (قد يؤثر على مريض واحد من كل 10000 مريض)، وتتضمن العلامات:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، الشفتين، الفم، اللسان، أو الحلق، وھو ما قد يسبب صعوبة البلع أو التنفس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي حكّي.</p><p dir="RTL">اتصل بطبيبك أو احصل على المعونة الطبية الطارئة فورا ً إذا لاحظت أي من ھذه العلامات، وقد يقرر طبيبك أن جورنيستا لا يلائمك.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>ردود فعل تحسسية</strong> &ndash; وھي غير شائعة في الأشخاص الذين يتناولون جورنيستا (قد يؤثر على مريض واحد من كل 100 مريض)، وتتضمن العلامات:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، الشفتين، الفم، اللسان، أو الحلق، وھو ما قد يسبب صعوبة البلع أو التنفس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي حكّي.</p><p dir="RTL">اتصل بطبيبك أو احصل على المعونة الطبية الطارئة فورا ً إذا لاحظت أي من ھذه العلامات، وقد يقرر طبيبك أن جورنيستا لا يلائمك.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى&nbsp; </strong></p><p dir="RTL"><strong>آثار جانبية بالغة الشيوع (قد تؤثر على أكثر من </strong>مريض واحد<strong> من كل </strong><strong>10</strong> مرضى<strong>)&nbsp; </strong> الإمساك، الغثيان، والقيء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس، الضعف أو الدوخة، والصداع.</p><p>&nbsp;</p><p dir="RTL"><strong>أعراض جانبية شائعة </strong><strong>&nbsp;</strong></p><p dir="RTL"><strong>(قد تؤثر على </strong>مريض واحد <strong>تقريبا من كل </strong><strong>100</strong><strong> مريض)&nbsp; </strong></p><p><strong>&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسھال، آلام المعدة، التھاب المعدة والأمعاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الھضم، تفاقم ارتجاع الطعام إلى الحلق (حُرقة الفؤاد)، وجفاف الفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف، ضعف الشھية وفقد الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبصار أو سماع أشياء غير موجودة (ھلوسات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتشوش، أو القلق، أو العصبية، أو التململ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب جديد، أو تفاقم الاكتئاب السابق، والتغيرات المزاجية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوخة، وعسر النوم (الأرق)، والأحلام غير الطبيعية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النسيان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرعشة أو التشنج العضلي، النخز أو التنميل بالجلد، وضعف الإحساس باللمس أو الحس، خاصة بالجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش الرؤية، والإحساس بالدوران (الدوار)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط التعرق، الحكّة، الطفح الجلدي أو التوھج</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم، كألم المفاصل والعضلات والظھر أو الأطراف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم مع التبول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التوق بعد انسحاب الدواء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم نتيجة لاحتباس السوائل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحُمى أو قشعريرة البرد، الشعور بالإزعاج بالصدر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السقطات، والكدمات.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر على </strong>مريض واحد <strong>تقريبا من كل </strong><strong>100</strong><strong> مريض)&nbsp; </strong> صعوبة التنفس (الأزيز)، وقد يكون ذلك نتيجة لضيق مجرى الھواء بالرئتين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب أو انسداد الأمعاء، جيوب بالجدار الداخلي للقولون، البواسير</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات بالتبرز، كالتناوب بين الإمساك والإسھال، والبراز غير الطبيعي كالبراز المدمم، والانتفاخ، وتمرير الغازات، التجشؤ وصعوبة البلع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الشھية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات الھلع، الشعور بالزوران (جنون الشك)، والفتور، والاضطراب أو التوتر، والبكاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالسعادة البالغة (النشوة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الدافع الجنسي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات النوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات المخ (الاعتلال الدماغي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الانتباه أو الدراية، صعوبة التركيز، صعوبة تكوين كلمات أو التحدث بھا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف أو الإغماء، وفقد التناسق، ومشكلات الاتزان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتفاض غير المنضبط، الھزة، أو الحركة الالتوائية، الھزة المفاجئة للعضلات، وفرط الإحساس باللمس أو الحِس، خاصة بالجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير الإحساس بالطعم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواج الرؤية، جفاف العينين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين بالأذنين (طنين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات نبض القلب، كالنبضات المتخطاة، وتسارع النبض القلبي أو اضطرابه (الخفقان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات التبول، كعدم القدرة على التبول، صعوبة بدء التبول، أو زيادة مرات التبول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات بالممارسة الجنسية أو العجز الجنسي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيھة بالأنفلونزا، كالشعور بالحرارة أو البرودة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات المشي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعصبية، أو بحالة غير طبيعية أو غير جيدة بشكل عام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة الدواء المفرطة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص مستوى الأكسجين في الدم، نقص مستوى البوتاسيوم في الدم، نقص مستوى إنزيمات الكبد في الدم.</p><p>&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر على </strong>مريض واحد<strong> تقريبا من كل </strong><strong>1000</strong><strong> مريض)&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النفس السريع أو العميق (فرط التھوية)، العطس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثقب الأمعاء، انعدام الانقباض بجدار الأمعاء، التھاب الاثني عشر، والتمزقات الشرجية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور إفراغ المعدة، احتباس غلاف القرص بالمعدة، ومن ثمّ&nbsp; فشله في المرور عبر الأمعاء، ألم مع التبرز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدائية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات التشنجية أو الصرعية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التململ أو فرط النشاط، والإنعكاسات المفرطة أو الزائدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التفكير وتذكر المعلومات أو حل المشكلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صِغر البؤبؤين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تباطؤ النبض القلبي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالحرقة بالجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعطش أو الخُمار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حرارة الجسم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات أنزيم &quot;أميليز&quot; في الدم&nbsp;</p><p dir="RTL">زيادة مستويات حمض اليوريك في الدم، وھو ما قد يسبب النقرس&nbsp; نقص مستويات الھرمونات الجنسية، كنقص مستوى التستوستيرون في الدم&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا أصُبت بآثار جانبية، تحدث مع طبيبك أو الصيدلي، ويشمل ذلك أي آثار جانبية غير مذكورة في ھذه&nbsp; النشرة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب حفظ الدواء بعيدًا عن متناول الأطفال ونظرھم.&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL">لا تستخدم جورنيستا بعد تاريخ انتھاء الصلاحية على العبوة&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أقراص لا تحتاج إليھا من جورنيستا فلا تتخلص منھا في مياه الصرف الصحي ولا المخلفات المنزلية، وإنما اسأل الصيدلي عن كيفية التخلص من الادوية التي لا تحتاج اليھا، لأن ھذه التدابير ستساعد في حماية البيئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;‐ المادة الفعالة ھي ھيدرومورفون ھيدروكلوريد، وتأتي أقراص جورنيستا في تركيزات مختلفة.&nbsp;</p><p>&nbsp;</p><p dir="RTL">كل قرص 8 ملجم يحتوى على 8.72 ملجم، ويوفر 8 ملجم من ھيدرومورفون ھيدروكلوريد، بما يعادل 7.12 ملجم من ھيدرومورفون.&nbsp;</p><p dir="RTL">كل قرص 16 ملجم يحتوى على 16.35 ملجم، ويوفر 16 ملجم من ھيدرومورفون ھيدروكلوريد، بما يعادل 7.12 ملجم من ھيدرومورفون.&nbsp;</p><p dir="RTL">كل قرص 32 ملجم يحتوى على ويوفر 32 ملجم من ھيدرومورفون ھيدروكلوريد، بما يعادل 28.48 ملجم من ھيدرومورفون.&nbsp;</p><p dir="RTL">كل قرص 64 ملجم يحتوى على ويوفر 64 ملجم من ھيدرومورفون ھيدروكلوريد، بما يعادل 56.96 ملجم من ھيدرومورفون.&nbsp;</p><p dir="RTL">&nbsp;‐ المكونات الأخرى ھي:&nbsp;</p><p dir="RTL">بيوتريل ھيدروكسي تولوين، إي 321، سليولوز أسيتات، جليسرول ثلاثي الأسيتات، أكسيد الحديد الأسود إي 172، ھايبرميللوز، لاكتوز، ماكروجول، ماغنسيوم سيتريت، أكسيد البولي إيثيلين، بوفيدون، بروبيلين جليكول، كلوريد الصوديوم، ثاني أكسيد التيتانيوم إي 171.&nbsp;</p><p>&nbsp;</p><p dir="RTL">يحتوى قرص 8 ملجم على أكسيد الحديديك الأحمر إي 172.&nbsp;</p><p dir="RTL">كل من قرص 16 ملجم وقرص 32 ملجم يحتوى كذلك على أكسيد الحديديدك الأصفر إي 172.&nbsp;</p><p dir="RTL">يحتوي قرص 64 ملجم كذلك على صبغة نيلية قرمزية إي 132.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أشكال</strong><strong> </strong><strong>جورنيستا</strong><strong> </strong><strong>ومحتويات</strong><strong> </strong><strong>العبوة</strong><strong> </strong>&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">أقراص 8 ملجم حمراء، مدورة، ومطبوع عليھا &quot;HM8&quot; بالحبر الأسود على أحد الجانبين.&nbsp; أقراص 16 ملجم صفراء، مدورة، ومطبوع عليھا &quot;HM16&quot; بالحبر الأسود على أحد الجانبين.&nbsp; أقراص 32 ملجم بيضاء، مدورة، ومطبوع عليھا &quot;HM32&quot; بالحبر الأسود على أحد الجانبين.&nbsp; أقراص 64 ملجم زرقاء، مدورة، ومطبوع عليھا &quot;HM64&quot; بالحبر الأسود على أحد الجانبين.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>لم يتم ذكرها</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2012
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                JURNISTA® 8 mg prolonged-release tablets 
JURNISTA® 16 mg prolonged-release tablets 
JURNISTA® 32 mg prolonged-release tablets 
JURNISTA® 64 mg prolonged-release tablets 
Hydromorphone hydrochloride 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release tablets. 
8 mg tablets: Red, round, biconvex tablet, with ‘HM 8’ printed in black ink on one side. Each tablet  contains  8.72 mg  and  delivers  8  mg  hydromorphone  HCl,  equivalent  to  7.12 mg hydromorphone base. 
16 mg tablets: Yellow, round, biconvex tablet, with ‘HM 16’ printed in black ink on one side. Each tablet contains 16.35 mg and delivers 16 mg hydromorphone HCl, equivalent to 14.24 mg hydromorphone base. 
32 mg tablets: White, round, biconvex tablet, with ‘HM 32’ printed in black ink on one side. Each tablet contains and delivers 32.00 mg hydromorphone HCl, equivalent to 28.48 mg of hydromorphone base. 
64 mg tablets: Blue, round, biconvex tablet, with ‘HM 64’ printed in black ink on one side. Each tablet  contains  and  delivers  64.00 mg  hydromorphone  HCl,  equivalent  to  56.96 mg  of hydromorphone base. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                For excipients, see List of Excipients. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Indications</p><p>Treatment of moderate to severe pain.</p><p>JURNISTA<sup>&reg; </sup>should be used in patients requiring continuous analgesia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dosage and Administration</p><p>As with other opioid analgesics, safe and effective administration of JURNISTA<sup>&reg;&nbsp; </sup>to patients with pain depends upon a comprehensive assessment of the patient. The nature of the pain as well as the concurrent medical status of the patient will affect selection of the dose. Owing to the varied response observed to opioids between individuals, it is recommended that all patients be started at the lowest appropriate dose of opioid therapy and titrated to an adequate level of analgesia, balanced against an acceptable frequency of adverse reactions.</p><p>As with any strong opioid, appropriate prophylaxis for known adverse reactions (for example constipation), should be considered.</p><p>Dosage &ndash; Adults</p><p>JURNISTA<sup>&reg; </sup>should not be taken more than once every 24 hours.</p><p>Patients currently not routinely receiving opioids</p><p>The initial dose in patients currently not routinely receiving opioids should not exceed 8 mg every 24 hours.&nbsp; The dose may be titrated upwards, if required, in increments of the lowest available tablet strength, depending on response and supplementary analgesic requirements. The dosage should not be titrated more frequently than every fourth dose (for example, if the first dose is given on a Monday, the dosage could be increased no earlier than the fourth dose, on Thursday).</p><p>Because it may be more time consuming to titrate a patient to adequate analgesia using a controlled-release opioid preparation, it may be advisable to begin treatment with conventional immediate-release&nbsp; preparations&nbsp; (e.g.&nbsp; immediate-release&nbsp; hydromorphone&nbsp; or&nbsp; immediate-release morphine) and then convert to the appropriate total daily dose of JURNISTA<sup>&reg;</sup>. Use the conversion table provided below to calculate the conversion doses (Table 1).</p><p>Patients currently receiving opioids regularly</p><p>In patients currently taking opioid analgesics regularly, the starting dose of JURNISTA<sup>&reg; </sup>should be based on the prior daily opioid dose, using standard equianalgesic ratios. For opioids other than morphine, first estimate the equivalent total daily dose of morphine, then use Table 1 to determine the equivalent total daily dose of JURNISTA<sup>&reg;</sup>.</p><p>Table 1: Multiplication Factors for Converting the Daily Dose of Prior Opioids to the Daily <u>&nbsp;&nbsp;Dose of JURNISTA<sup>&reg;</sup>(mg/day Prior Opioid x Factor = mg/day JURNISTA<sup>&reg;</sup>)&nbsp; </u>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p><strong>Prior Opioid </strong></p></td><td><p><strong>Oral Prior Opioid</strong></p></td><td><p><strong>Parenteral Prior Opioid</strong></p></td></tr><tr><td><p><strong>&nbsp; </strong></p></td><td><p><strong>(factor)&nbsp; </strong></p></td><td><p><strong>(factor)&nbsp; </strong></p></td></tr><tr><td><p>Morphine&nbsp; Hydromorphone&nbsp;</p></td><td><p>0.2 1&nbsp;</p></td><td><p>0.6 4&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>No fixed conversion ratio is likely to be satisfactory in all patients, due to individual patient and formulation&nbsp;&nbsp; differences.&nbsp;&nbsp; Therefore,&nbsp;&nbsp; conversion&nbsp;&nbsp; to&nbsp;&nbsp; the&nbsp;&nbsp; recommended&nbsp;&nbsp; starting&nbsp;&nbsp; dose&nbsp;&nbsp; of JURNISTA<sup>&reg; </sup>followed by close patient monitoring and titration is advised.</p><p>Dosages should be rounded down to the closest dose of JURNISTA<sup>&reg; </sup>available, as clinically indicated.</p><p>Discontinue all other around-the-clock opioid analgesic medications when JURNISTA<sup>&reg; </sup>therapy is initiated.</p><p>JURNISTA<sup>&reg;&nbsp; </sup>can also be safely used with usual doses of non-opioid analgesics and analgesic adjuvants.</p><p>Individualization of dosage and maintenance of therapy</p><p>After initiation of therapy with JURNISTA<sup>&reg;</sup>, dose adjustments may be necessary to obtain the patient&rsquo;s best balance between pain relief and opioid-related adverse reactions.</p><p>If the pain increases in severity or analgesia is inadequate, a gradual increase in dosage may be required. In order to allow the effects of the dose change to stabilize, the dosage should be increased no more frequently than every fourth dose (for example, if the first dose is given on a Monday, the dosage could be increased no earlier than the fourth dose, on Thursday). As a guideline, dosage increases of 25-100% of the current daily dose of JURNISTA<sup>&reg; </sup>should be considered for each titration step.</p><p>Once patients become stable on once-daily JURNISTA<sup>&reg; </sup>therapy, the dose may be continued for as long as pain relief is necessary. The continued need for around-the-clock opioid therapy or adjustments in therapy should be reassessed periodically as appropriate.</p><p>Missed dose</p><p>If the patient did not take the regularly scheduled dose of JURNISTA<sup>&reg;</sup>, the patient should be instructed to take the next dose immediately and start a new 24-hour regimen.</p><p>Stopping treatment</p><p>In patients who are physically dependent on opioids and receiving daily administration of hydromorphone, abrupt discontinuation of treatment with JURNISTA<sup>&reg; </sup>will result in symptoms of withdrawal syndrome. Therefore, if cessation of therapy with JURNISTA<sup>&reg; </sup>is indicated in patients, the dose of JURNISTA<sup>&reg; </sup>should be reduced by 50% every 2 days until the lowest possible dose is reached, at which time therapy may be safely discontinued. If symptoms of withdrawal appear, tapering should be stopped. The dose should be slightly increased until the signs and symptoms of opioid withdrawal disappear. Tapering should then begin again but with longer periods of time between each JURNISTA<sup>&reg; </sup>dose reduction, or before converting to an equianalgesic dose of another opioid to continue tapering.</p><p>Special populations</p><p>Pediatrics (below age 18)</p><p>JURNISTA<sup>&reg; </sup>is not recommended for use in children and adolescents below age 18 due to insufficient data on safety and efficacy (see Contraindications).</p><p>Elderly</p><p>The&nbsp; medical&nbsp; status&nbsp; of&nbsp; the &nbsp;elderly&nbsp; patient&nbsp; is&nbsp; often&nbsp; complex.&nbsp; Therefore,&nbsp; treatment&nbsp; with JURNISTA<sup>&reg; </sup>should be initiated cautiously at a reduced initial dose (see Pharmacokinetic Properties &ndash; Elderly). <em>Renal impairment</em></p><p>Following single-dose administration of hydromorphone immediate-release tablets, the following results were observed in clinical studies:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with moderate renal insufficiency (creatinine clearance of 40-60 mL/min), exposure (plasma AUC) to hydromorphone was approximately 2 times higher than in those with normal renal function and elimination half-life was unaltered.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with severe renal insufficiency (creatinine clearance &lt; 30 mL/min), exposure (plasma AUC) to hydromorphone was approximately 4 times greater than in those with normal renal function and elimination half-life 3 times longer.</p><p>Therefore, patients with moderate renal insufficiency should be started on a reduced dose and closely monitored during dose titration. In patients with severe renal insufficiency an increased dosing interval should also be considered and these patients should in addition be monitored during maintenance therapy for development of opioid-related adverse reactions.</p><p>Hepatic impairment</p><p>Following single-dose administration of hydromorphone immediate-release tablets, the following results were observed in clinical studies:</p><p>&bull; In patients with moderate hepatic insufficiency (scoring 7-9 on Child-Pugh rating scale) both exposure (plasma AUC) and peak plasma concentrations of hydromorphone were approximately 4-times higher compared with healthy controls and elimination half-life was unaltered.</p><p>Therefore, patients with moderate hepatic insufficiency should be started on a reduced dose and closely monitored during dose titration.</p><p>Administration</p><p>Patients should be instructed to swallow the JURNISTA<sup>&reg; </sup>tablet whole with a glass of water, at approximately the same time each day, and never to chew, divide, or crush it. JURNISTA<sup>&reg; </sup>may be taken with or without food (see <em>Pharmacokinetic Properties &ndash; Absorption</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                JURNISTA® is contraindicated in: 
•	Patients  with  a  known  hypersensitivity  to  hydromorphone  or  to  any  of  the  tablet excipients. 
•	Patients who have had surgical procedures and/or underlying disease that would result in narrowing of the gastrointestinal tract, or have “blind loops” of the gastrointestinal tract or gastrointestinal obstruction. 
•	The management of acute or post-operative pain. 
•	Patients with status asthmaticus. 
•	Children, or during pregnancy, labor, and delivery

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypotension</p><p>Opioid analgesics, including hydromorphone, may cause severe hypotension in an individual whose ability to maintain blood pressure is compromised by a depleted blood volume or concomitant administration of drugs such as phenothiazines or general anesthetics.</p><p>Paralytic ileus</p><p>JURNISTA<sup>&reg; </sup>should not be used in situations with risk of paralytic ileus. If during treatment, paralytic ileus is suspected, treatment with JURNISTA<sup>&reg; </sup>should be stopped.</p><p>Impaired respiration</p><p>Respiratory depression is the most important hazard of opioid preparations and occurs most frequently in overdose situations, in the elderly, in the debilitated, and in those suffering from conditions accompanied by hypoxia or hypercapnia when even moderate doses may dangerously decrease respiration. JURNISTA<sup>&reg;</sup>, like all other opioids, should be used with extreme caution in patients with a substantially decreased respiratory reserve or pre-existing respiratory depression and in patients with chronic obstructive pulmonary disease. Severe pain antagonizes the respiratory depressant effects of opioids. However, should pain suddenly subside, these effects may rapidly become manifest. Patients who are scheduled for regional anesthetic procedures or other&nbsp; interruptions&nbsp; of&nbsp; pain&nbsp; transmission&nbsp; pathways&nbsp; should&nbsp; not&nbsp; receive&nbsp; JURNISTA<sup>&reg;&nbsp;&nbsp; </sup>within 24 hours of the procedure. Concomitant administration of hydromorphone with other opioid analgesics is associated with an increased risk of respiratory failure. Therefore, it is important to reduce the dose of hydromorphone when other analgesics are given concomitantly.</p><p>Head injury and increased intracranial pressure</p><p>The&nbsp; respiratory&nbsp; depressant&nbsp; effects&nbsp; of&nbsp; opioids&nbsp; with&nbsp; carbon&nbsp; dioxide&nbsp; retention&nbsp; and&nbsp; secondary elevation of cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury or raised intracranial pressure. Opioids produce effects that may obscure neurological signs of further increases in intracranial pressure in patients with head injuries. JURNISTA<sup>&reg; </sup>should only be administered under such circumstances when considered essential and then with extreme caution.</p><p>Gastrointestinal tract and other smooth muscle</p><p>Like other opioids, hydromorphone causes a reduction in gastrointestinal motility associated with an increase in smooth muscle tone. Consequently, constipation is a frequent side effect reported with treatment with opioids. Patients should be advised on measures to prevent constipation and prophylactic laxative use should be considered. Extra caution should be used in patients with chronic constipation.</p><p>Clinical conditions or medicinal products that cause a sudden and significant shortening of gastrointestinal&nbsp;&nbsp; transit&nbsp;&nbsp; time&nbsp;&nbsp; may&nbsp;&nbsp; result&nbsp;&nbsp; in&nbsp;&nbsp; decreased&nbsp;&nbsp; hydromorphone&nbsp;&nbsp; absorption&nbsp;&nbsp; with JURNISTA<sup>&reg; </sup>and may potentially lead to withdrawal symptoms in patients with a physical dependence on opioids.</p><p>The administration of opioids may obscure the diagnosis or clinical course of acute abdominal conditions. Therefore it is important to make sure that the patient is not suffering from intestinal occlusion, especially of the ileus, before initiation of treatment. Hydromorphone also can cause an increase in biliary tract pressure as a result of spasm in the sphincter of Oddi. Caution should therefore be exercised in the administration of JURNISTA<sup>&reg; </sup>to patients with inflammatory or obstructive bowel disorders, acute pancreatitis secondary to biliary tract disease and in patients about to undergo biliary surgery.</p><p>The JURNISTA<sup>&reg; </sup>tablet is non-deformable and does not appreciably change in shape in the gastrointestinal tract. There have been very rare reports of obstructive symptoms in patients with known strictures in association with ingestion of medicinal products in non-deformable controlled-release formulations (see Contraindications).</p><p>Patients should be advised not to be alarmed if they notice what appears to be the JURNISTA<sup>&reg;</sup><sub> </sub>tablet in their stools, as it is simply the non-dissolvable shell.</p><p>Special risk patients</p><p>JURNISTA<sup>&reg;</sup>, like all opioid analgesics, should be administered with caution and in reduced dosages&nbsp; in&nbsp; patients&nbsp; with&nbsp; moderate&nbsp; to&nbsp; severe&nbsp; renal&nbsp; or&nbsp; hepatic&nbsp; insufficiency,&nbsp; adrenocortical insufficiency, myxedema, hypothyroidism, prostatic hypertrophy or urethral stricture. Caution should also be exercised in the administration of JURNISTA<sup>&reg;&nbsp; </sup>to patients with central nervous system depression, kyphoscoliosis, toxic psychosis, acute alcoholism, delirium tremens, or convulsive disorders.</p><p>JURNISTA<sup>&reg; </sup>should not be used during breast-feeding.</p><p>Use in renal and hepatic impairment</p><p>Patients with either moderate hepatic or renal insufficiency should be started on a reduced dose and closely monitored during dose titration. In patients with severe renal insufficiency an increased dosing interval should also be considered and these patients should in addition be monitored during maintenance therapy for development of opioid-related adverse reactions (see Dosage and Administration &ndash; Special populations).</p><p>Use in the elderly</p><p>Elderly&nbsp; patients&nbsp; are&nbsp; more&nbsp; prone&nbsp; to&nbsp; central&nbsp; nervous&nbsp; system&nbsp; adverse&nbsp; effects&nbsp; (confusion)&nbsp; and gastrointestinal disturbances, and physiological reduction of renal function. Therefore, extra caution should be shown, and the initial dose should be reduced. Concomitant use of other medications, especially tricyclic antidepressants, increases the risk of confusion and constipation. Diseases of the prostate gland and the urinary tract are often seen in the elderly. This contributes to the increased risk of urinary retention. The above considerations emphasize the importance of caution rather than imply a restriction on the use of opioids in the elderly.</p><p>Drug dependence, drug abuse, and use with alcohol</p><p>Physical dependence is a state of adaptation that is manifested by an opioid specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.</p><p>The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, piloerection, myalgia, mydriasis, irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. In general, opioids should not be abruptly discontinued (see Dosage and Administration &ndash; Stopping treatment).</p><p>JURNISTA<sup>&reg;&nbsp; </sup>should be used with caution in patients with alcoholism and other drug dependencies due to the increased frequency of opioid tolerance and psychological dependence observed in these patient populations. With abuse by parenteral routes, the tablet excipients may cause lethal complications.</p><p>Since alcohol increases the sedative effect of hydromorphone concomitant use of JURNISTA<sup>&reg;</sup><sub> </sub>and alcohol should be avoided.</p><p>Lactose</p><p>JURNISTA<sup>&reg;&nbsp; </sup>contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp deficiency, or glucose-galactose malabsorption should not take this medicine.</p><p>Sulfite allergy</p><p>JURNISTA<sup>&reg; </sup>may contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Monoamine oxidase inhibitors</p><p>Monoamine oxidase inhibitors (MAOIs) may cause central nervous system excitation or depression, hypotension or hypertension if co-administered with opioids. JURNISTA<sup>&reg; </sup>is not intended for patients taking MAOIs or within 14 days of stopping such treatment.</p><p>Morphine agonists/antagonists</p><p>The concomitant use of hydromorphone with morphine agonists/antagonists (buprenorphine, nalbuphine,&nbsp; pentazocine)&nbsp; could&nbsp; lead&nbsp; to&nbsp; a&nbsp; reduction&nbsp; of&nbsp; the&nbsp; analgesic&nbsp; effect&nbsp; by&nbsp; competitive blocking of receptors, thus leading to risk of withdrawal symptoms. Therefore, this combination is not recommended.</p><p>Central nervous system depressants</p><p>The concomitant use of central nervous system depressants such as hypnotics, sedatives, general anesthetics, antipsychotics and alcohol may cause additive depressant effects and respiratory depression. Additionally, hypotension and profound sedation or coma may occur. When this combination is indicated, the dose of one or both agents should be reduced. <strong><em>Muscle relaxants</em></strong></p><p>JURNISTA<sup>&reg;</sup>, like other opioids, may enhance the neuromuscular blocking action of muscle relaxants and cause an increased degree of respiratory depression.</p><p>Alcohol</p><p>The concomitant use of alcohol should be avoided. Alcohol increases the sedative effect of hydromorphone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy Category C. </em><strong>&nbsp;</strong></p><p>JURNISTA&reg; has been shown to have an embryocidal effect in rat when given in doses resulting in ~1.5 times the exposure from the median human dose (see Non-Clinical information section). There are no adequate and well-controlled studies in pregnant women. JURNISTA&reg; is contraindicated during pregnancy, labor and delivery.</p><p>Hydromorphone has been shown to cross the placental barrier in experimental animals. The potential teratogenic risk for humans from use of hydromorphone and other opioids during pregnancy is unknown.</p><p>JURNISTA&reg; should not be used during pregnancy and labor due to impaireduterine contractility and the risk of neonatal respiratory depression. Withdrawal symptoms may be observed in the newborn of mothers undergoing chronic treatment. <strong>Breast-feeding </strong></p><p>Low concentrations of hydromorphone and other opioid analgesics have been detected in human milk in clinical studies. Preclinical studies have shown that hydromorphone can be detected in milk of lactating rats. JURNISTA&reg; should not be used during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>JURNISTA<sup>&reg; </sup>can have a major influence on the ability to drive and use machines. This is particularly likely at the start of therapy, following an increase in dose or change of preparation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Throughout this section, adverse reactions are presented. Adverse reactions are adverse events that were considered to be reasonably associated with the use of hydromorphone hydrochloride based on the comprehensive assessment of the available adverse event information. A causal relationship&nbsp; with&nbsp; hydromorphone&nbsp; hydrochloride&nbsp; cannot&nbsp; be&nbsp; reliably established&nbsp; in&nbsp; individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. <strong><em>Clinical Trial Data</em></strong></p><p>Placebo-controlled double-blind data &ndash; adverse reactions reported at <sub>&ge;</sub>1% incidence</p><p>The safety of JURNISTA<sup>&reg;&nbsp; </sup>was evaluated in 788 patients who participated in 2 multicenter, double-blind, randomized, placebo-controlled clinical trials in patients with osteoarthritis<em>, </em>who received&nbsp; at&nbsp; least&nbsp; one&nbsp; dose&nbsp; of&nbsp; JURNISTA<sup>&reg;&nbsp;&nbsp; </sup>(Studies&nbsp; M03-644-05&nbsp; and&nbsp; 42801PAI3001)&nbsp; and provided safety data. The drug titration phases lasted up to 4 weeks, and maintenance phases were 12 weeks at doses of 8 to 32 mg/day; Study M03-644-05 also included a taper phase of up</p><p>to 1 week. Adverse reactions reported for <sub>&ge;1</sub>% of JURNISTA<sup>&reg;</sup>-treated patients and with an incidence greater than placebo-treated patients are shown in Table 2.</p><p>Table 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions Reported by <sub>&ge;1</sub>% of JURNISTA<sup>&reg;</sup>-Treated Patient and with&nbsp;&nbsp;&nbsp; an&nbsp;&nbsp;&nbsp; Incidence&nbsp;&nbsp;&nbsp; Greater&nbsp;&nbsp;&nbsp; than&nbsp;&nbsp;&nbsp; Placebo-Treated&nbsp;&nbsp;&nbsp; Patients&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp; 2 Double-Blind, Placebo-Controlled Clinical Trials of JURNISTA<sup>&reg;</sup><sub> </sub></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong> Adverse Reaction</p></td><td><p>&nbsp;</p></td><td><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_27239"
   o:spid="_x0000_s1056" style='width:474.95pt;height:.6pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="60318,73" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_993" o:spid="_x0000_s1057" style='position:absolute;
    width:60318;height:0;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="6031865,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l6031865,e" filled="f" strokeweight=".58pt">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,6031865,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="634" height="2" src="file:///C:/Users/falmajmo/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1028" type="#_x0000_t75" style='width:474.95pt;height:.6pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p></td><td><p><strong>JURNISTA<sup>&reg;</sup></strong><sub> </sub><strong>%</strong></p></td><td><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p><p><strong>%</strong></p></td></tr><tr><td><p><strong><u>&nbsp;&nbsp; </u></strong></p><p><strong>Infections and infestations</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p><strong><u>(N=788)&nbsp; </u></strong></p></td><td><p>&nbsp;</p></td><td><p><strong><u>(N=481)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></strong><strong>&nbsp;</strong></p></td></tr><tr><td><p>Gastroenteritis</p><p><strong>Metabolism and nutrition disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>2.2</p></td><td><p>&nbsp;</p></td><td><p>0.6</p></td></tr><tr><td><p>Decreased appetite <strong>Psychiatric disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>4.6</p></td><td><p>&nbsp;</p></td><td><p>0.8</p></td></tr><tr><td><p>Insomnia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>4.3</p></td><td><p>&nbsp;</p></td><td><p>2.5</p></td></tr><tr><td><p>Anxiety</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>2.2</p></td><td><p>&nbsp;</p></td><td><p>0.8</p></td></tr><tr><td><p>Depression</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>1.6</p></td><td><p>&nbsp;</p></td><td><p>0.2</p></td></tr><tr><td><p>Nervousness</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>1.4</p></td><td><p>&nbsp;</p></td><td><p>0.2</p></td></tr><tr><td><p>Confusional state</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>1.3</p></td><td><p>&nbsp;</p></td><td><p>0</p></td></tr><tr><td><p>Abnormal dreams</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>1.0</p></td><td><p>&nbsp;</p></td><td><p>0</p></td></tr><tr><td><p>Libido decreased</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>1.0</p></td><td><p>&nbsp;</p></td><td><p>0</p></td></tr><tr><td><p><strong>Nervous system disorders</strong> Somnolence</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>18.7</p></td><td><p>&nbsp;</p></td><td><p>7.9</p></td></tr><tr><td><p>Dizziness</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>12.3</p></td><td><p>&nbsp;</p></td><td><p>5.2</p></td></tr><tr><td><p>Headache</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>11.7</p></td><td><p>&nbsp;</p></td><td><p>8.9</p></td></tr><tr><td><p>Paraesthesia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>1.1</p></td><td><p>&nbsp;</p></td><td><p>0.8</p></td></tr><tr><td><p>Tremor</p><p><strong>Ear and labyrinth disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>1.0</p></td><td><p>&nbsp;</p></td><td><p>0.4</p></td></tr><tr><td><p>Vertigo</p><p><strong>Cardiac disorders</strong> Palpitations</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>2.5</p><p>1.1</p></td><td><p>&nbsp;</p></td><td><p>1.2</p><p>0.2</p></td></tr><tr><td><p><strong>Vascular disorders</strong></p></td><td><p>&nbsp;</p></td><td rowspan="2"><p>&nbsp;</p></td><td rowspan="2"><p>1.0</p></td><td rowspan="2"><p>&nbsp;</p></td><td rowspan="2"><p>0.4</p></td></tr><tr><td colspan="2"><p>Flushing</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td colspan="2"><p>Dyspnoea</p><p><strong>Gastrointestinal disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>1.3</p></td><td><p>&nbsp;</p></td><td><p>0.4</p></td></tr><tr><td colspan="2"><p>Constipation</p></td><td><p>&nbsp;</p></td><td><p>44.4</p></td><td><p>&nbsp;</p></td><td><p>11.0</p></td></tr><tr><td colspan="2"><p>Nausea</p></td><td><p>&nbsp;</p></td><td><p>32.7</p></td><td><p>&nbsp;</p></td><td><p>8.7</p></td></tr><tr><td colspan="2"><p>Vomiting</p></td><td><p>&nbsp;</p></td><td><p>10.4</p></td><td><p>&nbsp;</p></td><td><p>1.9</p></td></tr><tr><td colspan="2"><p>Diarrhea</p></td><td><p>&nbsp;</p></td><td><p>6.9</p></td><td><p>&nbsp;</p></td><td><p>6.7</p></td></tr><tr><td colspan="2"><p>Dry mouth</p></td><td><p>&nbsp;</p></td><td><p>6.1</p></td><td><p>&nbsp;</p></td><td><p>3.3</p></td></tr><tr><td colspan="2"><p>Abdominal pain</p></td><td><p>&nbsp;</p></td><td><p>5.7</p></td><td><p>&nbsp;</p></td><td><p>2.7</p></td></tr><tr><td colspan="2"><p>Dyspepsia</p></td><td><p>&nbsp;</p></td><td><p>2.4</p></td><td><p>&nbsp;</p></td><td><p>2.1</p></td></tr><tr><td colspan="2"><p>Flatulence</p><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>1.4</p></td><td><p>&nbsp;</p></td><td><p>0.8</p></td></tr><tr><td colspan="2"><p>Pruritus</p></td><td><p>&nbsp;</p></td><td><p>10.8</p></td><td><p>&nbsp;</p></td><td><p>1.9</p></td></tr><tr><td colspan="2"><p>Hyperhidrosis</p></td><td><p>&nbsp;</p></td><td><p>3.2</p></td><td><p>&nbsp;</p></td><td><p>0</p></td></tr><tr><td colspan="2"><p>Rash</p><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>1.8</p></td><td><p>&nbsp;</p></td><td><p>1.0</p></td></tr><tr><td colspan="3"><p>Arthralgia</p><p><strong>General disorders and administration site conditions</strong></p></td><td><p>2.5</p></td><td><p>&nbsp;</p></td><td><p>1.7</p></td></tr><tr><td colspan="3"><p>Asthenia</p></td><td><p>9.1</p></td><td><p>&nbsp;</p></td><td><p>2.9</p></td></tr><tr><td colspan="3"><p>Oedema</p></td><td><p>2.4</p></td><td><p>&nbsp;</p></td><td><p>1.7</p></td></tr><tr><td colspan="3"><p>Pyrexia</p></td><td><p>1.3</p></td><td><p>&nbsp;</p></td><td><p>0.4</p></td></tr><tr><td colspan="3"><p>Chest discomfort <strong>Investigations</strong></p></td><td><p>1.1</p></td><td><p>&nbsp;</p></td><td><p>0.8</p></td></tr><tr><td colspan="3"><p>Weight decreased</p><p><strong>Injury, poisoning and procedural complications</strong></p></td><td><p>1.3</p></td><td><p>&nbsp;</p></td><td><p>0.2</p></td></tr><tr><td colspan="3"><p>Fall</p></td><td><p>1.6</p></td><td><p>&nbsp;</p></td><td><p>1.2</p></td></tr></tbody></table><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contusion &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.1</p><p><img width="2" height="1" src="file:///C:/Users/falmajmo/AppData/Local/Temp/3/msohtmlclip1/01/clip_image003.gif" /><em>Comparator-controlled and extension study data &ndash; adverse reactions reported at 1% incidence </em>Adverse reactions not reported in Table 2 that were reported by &ge;1% of JURNISTA<sup>&reg;</sup>-treated patients (N=2340) in 11 clinical trials (including the 2 placebo-controlled trials presented in <sup>&nbsp;</sup>Table 3)&nbsp; and&nbsp; 3 extension&nbsp; studies&nbsp; of&nbsp; JURNISTA<sup>&reg;&nbsp;&nbsp; </sup>in&nbsp; the&nbsp; treatment&nbsp; of&nbsp; chronic&nbsp; malignant&nbsp; or nonmalignant pain are shown in Table 3. All patients received at least one dose of JURNISTA<sup>&reg; </sup>and provided safety data.</p><p>Table 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;Adverse Reactions Reported by <sub>&ge;1%</sub> of JURNISTA<sup>&reg;</sup>-Treated&nbsp; Patients in</p><p>11 Clinical Trials and 3 Extension Studies of JURNISTA<sup>&reg;</sup><sub> </sub></p><p><strong>&reg;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong> Adverse Reaction</p></td><td><p><strong>JURNISTA</strong></p><p><strong>% </strong></p><p><strong>(N=2340)</strong></p></td></tr><tr><td><p><strong>Metabolism and nutrition disorders</strong> Dehydration</p></td><td><p>1.5</p></td></tr><tr><td><p><strong>Psychiatric disorders</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>Restlessness</p></td><td><p>1.7</p></td></tr><tr><td><p>Mood altered</p></td><td><p>1.2</p></td></tr><tr><td><p>Hallucination</p></td><td><p>1.1</p></td></tr><tr><td><p><strong>Nervous system disorders</strong> Sedation</p></td><td><p>1.7</p></td></tr><tr><td><p>Hypoaesthesia</p></td><td><p>1.6</p></td></tr><tr><td><p>Memory impairment</p></td><td><p>1.2</p></td></tr><tr><td><p><strong>Eye disorders</strong> Vision blurred</p></td><td><p>1.9</p></td></tr><tr><td><p><strong>Vascular disorders</strong> Hypertension</p></td><td><p>2.2</p></td></tr><tr><td><p><strong>Gastrointestinal disorders</strong> Oesophageal reflux aggravated</p></td><td><p>1.2</p></td></tr><tr><td><p><strong>Musculoskeletal and connective tissue disorders</strong> Back pain</p></td><td><p>3.9</p></td></tr><tr><td><p>Muscle spasms</p></td><td><p>3.8</p></td></tr><tr><td><p>Pain in extremity</p></td><td><p>2.7</p></td></tr><tr><td><p>Myalgia</p></td><td><p>1.0</p></td></tr><tr><td><p><strong>Renal and urinary disorders</strong> Dysuria</p></td><td><p>1.3</p></td></tr><tr><td><p><strong>General disorders and administration site conditions</strong> Pain</p></td><td><p>2.5</p></td></tr><tr><td><p>Drug withdrawal syndrome</p></td><td><p>2.2</p></td></tr><tr><td><p>Chills</p></td><td><p>1.2</p></td></tr></tbody></table><p><em>Comparator-controlled and extension study data &ndash; adverse reactions reported at &lt;1% incidence</em> Adverse reactions reported by &lt;1% of JURNISTA<sup>&reg;</sup>-treated patients (N=2340) in the above clinical trial dataset are shown in Table 4.</p><p>Table 4. Adverse Reactions Reported by &lt;1% of JURNISTA<sup>&reg;</sup>-Treated Patients in 11 Clinical Trials and 3 Extension Studies of JURNISTA<sup>&reg;</sup><sub> </sub></p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp; <strong>System Organ Class</strong></p><p>Adverse Reaction</p><p><strong>Infections and infestations</strong></p></td><td><p>&nbsp;</p></td><td><p><strong>JURNISTA<sup>&reg;</sup></strong><sub> </sub></p><p><strong>% </strong></p><p><strong>(N=2340)</strong></p></td></tr><tr><td><p>Diverticulitis</p><p><strong>Endocrine disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>0.21</p></td></tr><tr><td><p>Hypogonadism</p><p><strong>Metabolism and nutrition disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>0.04</p></td></tr><tr><td><p>Fluid retention</p></td><td><p>&nbsp;</p></td><td><p>0.30</p></td></tr><tr><td><p>Increased appetite</p></td><td><p>&nbsp;</p></td><td><p>0.30</p></td></tr><tr><td><p>Hyperuricaemia <strong>Psychiatric disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>0.09</p></td></tr><tr><td><p>Sleep disorder</p></td><td><p>&nbsp;</p></td><td><p>0.64</p></td></tr><tr><td><p>Panic attack</p></td><td><p>&nbsp;</p></td><td><p>0.34</p></td></tr><tr><td><p>Dysphoria</p></td><td><p>&nbsp;</p></td><td><p>0.17</p></td></tr><tr><td><p>Paranoia</p></td><td><p>&nbsp;</p></td><td><p>0.17</p></td></tr><tr><td><p>Euphoric mood</p></td><td><p>&nbsp;</p></td><td><p>0.13</p></td></tr><tr><td><p>Listless</p></td><td><p>&nbsp;</p></td><td><p>0.13</p></td></tr><tr><td><p>Aggression</p><p><strong>Nervous system disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>0.09</p></td></tr><tr><td><p>Dysgeusia</p></td><td><p>&nbsp;</p></td><td><p>0.94</p></td></tr><tr><td><p>Disturbance in attention</p></td><td><p>&nbsp;</p></td><td><p>0.85</p></td></tr><tr><td><p>Dysarthria</p></td><td><p>&nbsp;</p></td><td><p>0.64</p></td></tr><tr><td><p>Syncope</p></td><td><p>&nbsp;</p></td><td><p>0.64</p></td></tr><tr><td><p>Depressed level of consciousness</p></td><td><p>&nbsp;</p></td><td><p>0.43</p></td></tr><tr><td><p>Balance disorder</p></td><td><p>&nbsp;</p></td><td><p>0.43</p></td></tr><tr><td><p>Coordination abnormal</p></td><td><p>&nbsp;</p></td><td><p>0.38</p></td></tr><tr><td><p>Hyperaesthesia</p></td><td><p>&nbsp;</p></td><td><p>0.26</p></td></tr><tr><td><p>Myoclonus</p></td><td><p>&nbsp;</p></td><td><p>0.26</p></td></tr><tr><td><p>Dyskinesia</p></td><td><p>&nbsp;</p></td><td><p>0.21</p></td></tr><tr><td><p>Crying</p></td><td><p>&nbsp;</p></td><td><p>0.13</p></td></tr><tr><td><p>Encephalopathy</p></td><td><p>&nbsp;</p></td><td><p>0.13</p></td></tr><tr><td><p>Psychomotor hyperactivity</p></td><td><p>&nbsp;</p></td><td><p>0.09</p></td></tr><tr><td><p>Cognitive disorder</p></td><td><p>&nbsp;</p></td><td><p>0.09</p></td></tr><tr><td><p>Convulsion</p></td><td><p>&nbsp;</p></td><td><p>0.09</p></td></tr><tr><td><p>Hyperreflexia <strong>Eye disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>0.04</p></td></tr><tr><td><p>Diplopia</p></td><td><p>&nbsp;</p></td><td><p>0.34</p></td></tr><tr><td><p>Dry eye</p></td><td><p>&nbsp;</p></td><td><p>0.26</p></td></tr><tr><td><p>Miosis</p><p><strong>Ear and labyrinth disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>0.04</p></td></tr><tr><td><p>Tinnitus <strong>Cardiac disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>0.81</p></td></tr><tr><td><p>Tachycardia</p></td><td><p>&nbsp;</p></td><td><p>0.81</p></td></tr><tr><td><p>Extrasystoles</p></td><td><p>&nbsp;</p></td><td><p>0.17</p></td></tr><tr><td><p>Bradycardia</p></td><td><p>&nbsp;</p></td><td><p>0.09</p></td></tr><tr><td><p><strong>Vascular disorders</strong></p></td><td rowspan="2"><p>&nbsp;</p></td><td rowspan="2"><p>0.68</p></td></tr><tr><td><p>Hypotension</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p>Rhinorrhoea</p></td><td><p>&nbsp;</p></td><td><p>0.51</p></td></tr><tr><td><p>Respiratory distress</p></td><td><p>&nbsp;</p></td><td><p>0.26</p></td></tr><tr><td><p>Bronchospasm</p></td><td><p>&nbsp;</p></td><td><p>0.17</p></td></tr><tr><td><p>Hypoxia</p></td><td><p>&nbsp;</p></td><td><p>0.17</p></td></tr><tr><td><p>Respiratory depression</p></td><td><p>&nbsp;</p></td><td><p>0.13</p></td></tr><tr><td><p>Hyperventilation</p></td><td><p>&nbsp;</p></td><td><p>0.09</p></td></tr><tr><td><p>Sneezing</p><p><strong>Gastrointestinal disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>0.09</p></td></tr><tr><td><p>Dysphagia</p></td><td><p>&nbsp;</p></td><td><p>0.77</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:group id="Group_x0020_21888"
 o:spid="_x0000_s1042" style='position:absolute;left:0;text-align:left;
 margin-left:6pt;margin-top:1.85pt;width:474.95pt;height:.6pt;z-index:251660288;
 mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
 coordsize="60318,73" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_1565" o:spid="_x0000_s1043" style='position:absolute;
  width:60318;height:0;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="6031865,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l6031865,e" filled="f" strokeweight=".58pt">
  <v:stroke endcap="round"/>
  <v:path arrowok="t" textboxrect="0,0,6031865,0"/>
 </v:shape><w:wrap type="square"/>
</v:group><![endif]--><img width="634" height="2" src="file:///C:/Users/falmajmo/AppData/Local/Temp/3/msohtmlclip1/01/clip_image004.gif" /><!--[if gte vml 1]><v:group
 id="Group_x0020_21889" o:spid="_x0000_s1040" style='position:absolute;left:0;
 text-align:left;margin-left:6pt;margin-top:36.55pt;width:474.95pt;height:.6pt;
 z-index:251661312;mso-position-horizontal-relative:text;
 mso-position-vertical-relative:text' coordsize="60318,73" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_1589" o:spid="_x0000_s1041" style='position:absolute;
  width:60318;height:0;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="6031865,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l6031865,e" filled="f" strokeweight=".58pt">
  <v:stroke endcap="round"/>
  <v:path arrowok="t" textboxrect="0,0,6031865,0"/>
 </v:shape><w:wrap type="square"/>
</v:group><![endif]--><img width="634" height="2" src="file:///C:/Users/falmajmo/AppData/Local/Temp/3/msohtmlclip1/01/clip_image004.gif" /></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>System Organ Class</strong> Adverse Reaction</p></td><td><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_24447"
   o:spid="_x0000_s1038" style='width:474.95pt;height:.6pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="60318,73" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_1825" o:spid="_x0000_s1039" style='position:absolute;
    width:60318;height:0;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="6031865,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l6031865,e" filled="f" strokeweight=".58pt">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,6031865,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="634" height="2" src="file:///C:/Users/falmajmo/AppData/Local/Temp/3/msohtmlclip1/01/clip_image005.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1027" type="#_x0000_t75" style='width:474.95pt;height:.6pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p></td><td><p><strong>JURNISTA<sup>&reg;</sup></strong><sub> </sub></p><p><strong>% </strong></p><p><strong>(N=2340)</strong></p></td></tr><tr><td><p>Haematochezia</p></td><td><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_24556"
   o:spid="_x0000_s1036" style='width:474.95pt;height:.6pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="60318,73" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_1849" o:spid="_x0000_s1037" style='position:absolute;
    width:60318;height:0;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="6031865,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAKtmO4xQAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/dasIw
FL4XfIdwhN3ITBxDXGcqMnSMCYq6Bzg0x7a0OalNVrs9/TIQvDsf3+9ZLHtbi45aXzrWMJ0oEMSZ
MyXnGr5Om8c5CB+QDdaOScMPeVimw8ECE+OufKDuGHIRQ9gnqKEIoUmk9FlBFv3ENcSRO7vWYoiw
zaVp8RrDbS2flJpJiyXHhgIbeisoq47fVkP9vt59dvZ3up+Nq83ldFG43iqtH0b96hVEoD7cxTf3
h4nz588v8P9NPEGmfwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAKtmO4xQAAAN0AAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" path="m,l6031865,e" filled="f" strokeweight=".58pt">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,6031865,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="634" height="2" src="file:///C:/Users/falmajmo/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:474.95pt;height:.6pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p></td><td><p>0.64</p></td></tr><tr><td><p>Abdominal distension</p></td><td><p>&nbsp;</p></td><td><p>0.43</p></td></tr><tr><td><p>Haemorrhoids</p></td><td><p>&nbsp;</p></td><td><p>0.38</p></td></tr><tr><td><p>Abnormal faeces</p></td><td><p>&nbsp;</p></td><td><p>0.30</p></td></tr><tr><td><p>Intestinal obstruction</p></td><td><p>&nbsp;</p></td><td><p>0.21</p></td></tr><tr><td><p>Diverticulum</p></td><td><p>&nbsp;</p></td><td><p>0.13</p></td></tr><tr><td><p>Eructation</p></td><td><p>&nbsp;</p></td><td><p>0.13</p></td></tr><tr><td><p>Gastrointestinal motility disorder</p></td><td><p>&nbsp;</p></td><td><p>0.13</p></td></tr><tr><td><p>Ileus</p></td><td><p>&nbsp;</p></td><td><p>0.09</p></td></tr><tr><td><p>Large intestine perforation</p></td><td><p>&nbsp;</p></td><td><p>0.09</p></td></tr><tr><td><p>Anal fissure</p></td><td><p>&nbsp;</p></td><td><p>0.04</p></td></tr><tr><td><p>Bezoar</p></td><td><p>&nbsp;</p></td><td><p>0.04</p></td></tr><tr><td><p>Duodenitis</p></td><td><p>&nbsp;</p></td><td><p>0.04</p></td></tr><tr><td><p>Impaired gastric emptying</p></td><td><p>&nbsp;</p></td><td><p>0.04</p></td></tr><tr><td><p>Painful defaecation</p><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>0.04</p></td></tr><tr><td><p>Erythema</p></td><td><p>&nbsp;</p></td><td><p>0.43</p></td></tr><tr><td><p>Skin burning sensation <strong>Renal and urinary disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>0.04</p></td></tr><tr><td><p>Urinary retention</p></td><td><p>&nbsp;</p></td><td><p>0.90</p></td></tr><tr><td><p>Pollakiuria</p></td><td><p>&nbsp;</p></td><td><p>0.77</p></td></tr><tr><td><p>Urinary hesitation</p></td><td><p>&nbsp;</p></td><td><p>0.64</p></td></tr><tr><td><p>Micturition disorder</p><p><strong>Reproductive system and breast disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>0.38</p></td></tr><tr><td><p>Erectile dysfunction</p></td><td><p>&nbsp;</p></td><td><p>0.60</p></td></tr><tr><td colspan="2"><p>Sexual dysfunction</p><p><strong>General disorders and administration site conditions</strong></p></td><td><p>0.43</p></td></tr><tr><td colspan="2"><p>Influenza like illness</p></td><td><p>0.85</p></td></tr><tr><td colspan="2"><p>Malaise</p></td><td><p>0.77</p></td></tr><tr><td colspan="2"><p>Feeling of body temperature change</p></td><td><p>0.60</p></td></tr><tr><td colspan="2"><p>Feeling abnormal</p></td><td><p>0.38</p></td></tr><tr><td colspan="2"><p>Feeling jittery</p></td><td><p>0.30</p></td></tr><tr><td colspan="2"><p>Gait disturbance</p></td><td><p>0.17</p></td></tr><tr><td colspan="2"><p>Hangover</p></td><td><p>0.09</p></td></tr><tr><td colspan="2"><p>Feeling drunk <strong>Investigations</strong></p></td><td><p>0.04</p></td></tr><tr><td colspan="2"><p>Blood potassium decreased</p></td><td><p>0.98</p></td></tr><tr><td colspan="2"><p>Hepatic enzyme increased</p></td><td><p>0.30</p></td></tr><tr><td colspan="2"><p>Blood amylase increased</p></td><td><p>0.09</p></td></tr><tr><td colspan="2"><p>Blood testosterone decreased</p></td><td><p>0.04</p></td></tr><tr><td colspan="2"><p>Body temperature decreased</p><p><strong>Injury, poisoning and procedural complications</strong></p></td><td><p>0.04</p></td></tr><tr><td colspan="2"><p>&nbsp; <!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_25907"
   o:spid="_x0000_s1034" style='width:474.7pt;height:.5pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="60289,61" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_30002" o:spid="_x0000_s1035" style='position:absolute;
    width:60289;height:91;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="6028944,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l6028944,r,9144l,9144,,e" fillcolor="black" stroked="f"
    strokeweight="0">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,6028944,9144"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="633" height="2" src="file:///C:/Users/falmajmo/AppData/Local/Temp/3/msohtmlclip1/01/clip_image006.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1025" type="#_x0000_t75" style='width:474.7pt;height:.5pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Overdose&nbsp;</p></td><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.30&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Postmarketing data</p><p>In&nbsp; addition&nbsp; to&nbsp; the&nbsp; adverse&nbsp; reactions&nbsp; reported&nbsp; during&nbsp; clinical&nbsp; studies&nbsp; and&nbsp; listed&nbsp; above,&nbsp; the following adverse reactions have been reported during postmarketing experience. In Table 5, adverse reactions are presented by frequency category based on spontaneous reporting rates. The frequencies are provided according to the following convention:</p><p>Very common&nbsp;&nbsp; &ge; 1/10</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 1/100 and &lt; 1/10</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 1/ 1000 and &lt; 1/100</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 1/10000 and &lt; 1/1000</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1/10000, including isolated reports.</p><p><!--[if gte vml 1]><v:group id="Group_x0020_23946" o:spid="_x0000_s1032"
 style='position:absolute;left:0;text-align:left;margin-left:5.85pt;
 margin-top:29.1pt;width:482.05pt;height:.6pt;z-index:251662336' coordsize="61220,73"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_2067" o:spid="_x0000_s1033" style='position:absolute;
  width:61220;height:0;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="6122035,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l6122035,e" filled="f" strokeweight=".58pt">
  <v:stroke endcap="round"/>
  <v:path arrowok="t" textboxrect="0,0,6122035,0"/>
 </v:shape></v:group><![endif]--><img width="645" height="2" src="file:///C:/Users/falmajmo/AppData/Local/Temp/3/msohtmlclip1/01/clip_image007.gif" />Table 5. Adverse Reactions Identified During Postmarketing Experience with JURNISTA<sup>&reg; </sup>by Frequency Category Estimated from Spontaneous Reporting Rates</p><p><!--[if gte vml 1]><v:group id="Group_x0020_23947"
 o:spid="_x0000_s1030" style='position:absolute;left:0;text-align:left;
 margin-left:5.85pt;margin-top:24.3pt;width:482.05pt;height:.6pt;z-index:251663360'
 coordsize="61220,73" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_2068" o:spid="_x0000_s1031" style='position:absolute;
  width:61220;height:0;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="6122035,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l6122035,e" filled="f" strokeweight=".58pt">
  <v:stroke endcap="round"/>
  <v:path arrowok="t" textboxrect="0,0,6122035,0"/>
 </v:shape></v:group><![endif]--><img width="645" height="2" src="file:///C:/Users/falmajmo/AppData/Local/Temp/3/msohtmlclip1/01/clip_image008.gif" /><strong>System Organ Class</strong> Adverse Reaction</p><p><strong>Immune System Disorders</strong></p><p><!--[if gte vml 1]><v:group
 id="Group_x0020_23948" o:spid="_x0000_s1028" style='position:absolute;
 margin-left:5.85pt;margin-top:12.9pt;width:482.05pt;height:.6pt;z-index:251664384'
 coordsize="61220,73" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_2069" o:spid="_x0000_s1029" style='position:absolute;
  width:61220;height:0;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="6122035,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l6122035,e" filled="f" strokeweight=".58pt">
  <v:stroke endcap="round"/>
  <v:path arrowok="t" textboxrect="0,0,6122035,0"/>
 </v:shape></v:group><![endif]--><img width="645" height="2" src="file:///C:/Users/falmajmo/AppData/Local/Temp/3/msohtmlclip1/01/clip_image009.gif" />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Very rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Hypersensitivity</p><p><strong>Skin and subcutaneous disorders</strong></p><p><!--[if gte vml 1]><v:group
 id="Group_x0020_23949" o:spid="_x0000_s1026" style='position:absolute;
 margin-left:5.75pt;margin-top:11.15pt;width:482.5pt;height:.5pt;z-index:251665408'
 coordsize="61280,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_30004" o:spid="_x0000_s1027" style='position:absolute;
  width:61280;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="6128004,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l6128004,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke endcap="round"/>
  <v:path arrowok="t" textboxrect="0,0,6128004,9144"/>
 </v:shape></v:group><![endif]--><img width="643" height="1" src="file:///C:/Users/falmajmo/AppData/Local/Temp/3/msohtmlclip1/01/clip_image010.gif" /><em>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Angioedema, Urticaria&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms and signs</p><p>Opioid overdose is characterized by respiratory depression, drowsiness which progresses to stupor and coma, musculoskeletal flaccidity, cold skin, contracted pupils and, at times, tachycardia and hypotension. In cases of severe overdose, apnoea, circulatory collapse, cardiac arrest and death may occur.</p><p>Treatment</p><p>In&nbsp; the&nbsp; treatment&nbsp; of&nbsp; overdose,&nbsp; primary&nbsp; attention&nbsp; should&nbsp; be&nbsp; given&nbsp; to&nbsp; the&nbsp; reestablishment&nbsp; of adequate respiratory exchange keeping the airway open and instituting assisted or controlled ventilation.</p><p>Supportive measures (including oxygen and vasopressors) should be used to manage the shock and pulmonary edema which potentially accompany overdose. Cardiac arrest and arrhythmias may require cardiac massage or defibrillation.</p><p>In cases of severe overdose, specific antidotes such as naloxone and nalmefene should be used to manage respiratory depression (see the prescribing information for the specific opioid antagonist for details of proper use).&nbsp; The effect of naloxone is relatively short; therefore, the patient should be carefully monitored until respiration has stabilized. JURNISTA<sup>&reg; </sup>will release hydromorphone for approximately 24 hours. This should be taken into account in determining the treatment. Opioid antagonists should not be given in the absence of clinically significant respiratory depression&nbsp;&nbsp; or&nbsp;&nbsp; circulatory&nbsp; depression&nbsp;&nbsp; caused&nbsp;&nbsp; by&nbsp; opioids.&nbsp;&nbsp; Opioid&nbsp;&nbsp; antagonists&nbsp;&nbsp; should&nbsp;&nbsp; be administered with caution to patients suspected to be physically dependent on hydromorphone, since rapid reversal of an opioid, including hydromorphone, may precipitate symptoms of withdrawal.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic&nbsp; group:&nbsp; Analgesics;&nbsp; natural&nbsp; opium&nbsp; alkaloids,&nbsp; ATC&nbsp; code:&nbsp; N02AA03. Hydromorphone is a semisynthetic morphine derivative.</p><p>Mechanism of action</p><p>As with all opioid analgesics, hydromorphone exerts its principal pharmacological effects on the central nervous system and smooth muscle, including the gastrointestinal tract. These effects are expressed and modulated by binding to specific opioid receptors. Hydromorphone is principally an agonist of &micro;-receptors, showing a weak affinity for <sub>&kappa;</sub>-receptors. Analgesia occurs as a consequence of the binding of hydromorphone to the <sub>&micro;</sub>-receptors of the central nervous system. Although estimates vary (from 2 to 10 times), oral hydromorphone appears to be approximately 5 times as potent (by weight) as morphine.</p><p>&nbsp;</p><p>Pharmacodynamic effects</p><p>Respiratory depression occurs principally by direct action on the cerebral respiratory control centers. Opioids may cause nausea and vomiting due to direct stimulation of the chemoreceptors for emesis in the posterior area of the medulla.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Following a single oral dose of JURNISTA<sup>&reg; </sup>prolonged-release tablets (OROS<sup>&reg; </sup>Push-Pull<sup>TM </sup>Technology, developed by ALZA Corporation), plasma concentrations gradually increase over 6 to&nbsp; 8&nbsp; hours&nbsp; and&nbsp; thereafter&nbsp; concentrations&nbsp; are&nbsp; sustained&nbsp; for&nbsp; approximately&nbsp; 18&nbsp; to&nbsp; 24&nbsp; hours post-dose; the mean T<sub>max </sub>values were approximately 13 to 16 hours. This demonstrates that, as intended, hydromorphone is released in a controlled manner, consistent with once-daily dosing. The mean absolute bioavailability of hydromorphone after a single dose of 8, 16 or 32 mg of JURNISTA<sup>&reg; </sup>ranged from 22% to 26%. The concomitant administration of JURNISTA<sup>&reg; </sup>with a high fat meal has no effect on the absorption of hydromorphone.</p><p>Steady state plasma concentrations are approximately twice those observed following the first dose, and steady state is reached by the fourth dose of JURNISTA<sup>&reg;</sup>. No time dependent change in pharmacokinetics was seen with multiple dosing. At steady state, JURNISTA<sup>&reg;&nbsp; </sup>given once daily maintained hydromorphone plasma concentrations within the same concentration range as the immediate-release tablet given 4 times daily at the same total daily dose and diminishes the periodic fluctuations in plasma levels seen with the immediate-release tablet. The degree of fluctuation in plasma concentration at steady state during a 24-hour period was lower with JURNISTA<sup>&reg; </sup>(83%) as compared to the overall fluctuations of the immediate-release tablet (147%). At steady state, hydromorphone AUC for JURNISTA<sup>&reg; </sup>is equivalent to that observed for the immediate-release tablet.</p><p>Linear pharmacokinetics has been demonstrated for the prolonged-release tablet over the dose range 4 to 64 mg, with dose proportional increases in plasma concentrations (C<sub>max</sub>) and overall exposure (AUC).</p><p>Distribution</p><p>Plasma protein binding is low (&lt;30%). <strong><em>Metabolism</em></strong></p><p>Glucuronidation is the main metabolic pathway and the principal metabolite is the inactive hydromorphone&nbsp; 3-glucuronide,&nbsp; which&nbsp; follows&nbsp; a&nbsp; similar&nbsp; time&nbsp; course&nbsp; to&nbsp; hydromorphone&nbsp; in plasma. Unlike morphine, no active 6-glucuronide metabolite is produced.</p><p>Special populations Elderly</p><p>The effect of age on the single-dose pharmacokinetics of hydromorphone immediate-release resulted in a 14% decrease in C<sub>max </sub>and a modest increase (11%) in AUC in the elderly compared to the young. No difference in T<sub>max </sub>was observed. Greater sensitivity of older individuals cannot be excluded. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in this population.</p><p>Renal impairment</p><p>Renal impairment affected the pharmacokinetics of hydromorphone and its metabolite hydromorphone 3-glucuronide following administration of a single oral dose of the immediate- release tablet. The effects of renal impairment on hydromorphone pharmacokinetics were two- fold&nbsp; and&nbsp; four-fold&nbsp; increases&nbsp; in&nbsp; hydromorphone&nbsp; bioavailability&nbsp; in&nbsp; moderate&nbsp; and&nbsp; severe impairment, respectively. There were also substantial changes in hydromorphone 3-glucuronide elimination kinetics for the severe impairment group, although hemodialysis was effective at reducing plasma levels of both hydromorphone and metabolites. See Dosage and Administration &ndash; Special populations. <em>Hepatic impairment</em></p><p>In studies that used single oral dosing with conventional (immediate-release) tablets, hepatic impairment reduces the first-pass metabolism of hydromorphone such that four-fold higher plasma levels of hydromorphone are seen in subjects with moderate hepatic dysfunction. See Dosage and Administration &ndash; Special populations.</p><p>Gender</p><p>Hydromorphone&nbsp; plasma&nbsp; concentrations&nbsp; and&nbsp; pharmacokinetic&nbsp; parameters&nbsp; following administration of JURNISTA<sup>&reg; </sup>are comparable in male and female subjects.</p><p>Alcohol</p><p>In a study evaluating hydromorphone absorption from JURNISTA<sup>&reg; </sup>when taken with 240 mL of 4%, 20% and 40% alcohol, C<sub>max&nbsp; </sub>increased on average by 17, 31, and 28% respectively in the fasting&nbsp; state&nbsp; and&nbsp; was&nbsp; less&nbsp; affected&nbsp; in&nbsp; the&nbsp; fed&nbsp; state&nbsp; with&nbsp; increases&nbsp; of&nbsp; 14,&nbsp; 14,&nbsp; and&nbsp; 10%, respectively. Median T<sub>max </sub>(fasted and fed) with 4, 20 and 40% alcohol was 12 to 16 h and with 0% alcohol was 16 h. No effect was seen on AUC values both in the fed and fasted state.</p><p>Concomitant use of alcohol should be avoided (see Warnings and Precautions). Due to the OROS<sup>&reg;&nbsp; </sup>technology in JURNISTA<sup>&reg;</sup>, the prolonged-release properties of JURNISTA<sup>&reg; </sup>are maintained in the presence of alcohol. For the pharmacodynamic interactions, see Warnings and Precautions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical&nbsp; data&nbsp; from&nbsp; oral&nbsp; administration&nbsp; of&nbsp; hydromorphone&nbsp; reveal&nbsp; no&nbsp; special&nbsp; hazard&nbsp; for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, genotoxicity and fertility. The major effects were opioid-related pharmacological activities on the central nervous system and gastrointestinal tract, including dose-related increases in sedation, hyperactivity, sudden death, weight loss and decrease in food consumption.</p><p>Carcinogenicity</p><p>Long-term studies of hydromorphone showed no evidence of any carcinogenic effects after daily oral dosing for two years in mice and rats.&nbsp; The steady state plasma exposure (AUC, ng&bull;hr/mL) to hydromorphone in mice was approximately 0.46-times and in rats was greater than 3-times the human exposure following a single 64 mg dose of JURNISTA<sup>&reg;</sup>.</p><p>Reproductive Toxicology</p><p>In&nbsp; the&nbsp; rat,&nbsp; a&nbsp; slight&nbsp; but&nbsp; statistically&nbsp; significant&nbsp; reduction&nbsp; in&nbsp; implantations&nbsp; was&nbsp; observed&nbsp; at</p><p>6.25 mg/kg/day, a dose level that produced maternal toxicity during the mating period. Plasma exposure (AUC) to hydromorphone at this dose level was 135 ng&bull;hr/mL, providing a safety factor of about 1.5 over the human exposure (AUC) based on the median daily dose. Neonatal viability and survival were reduced in rats pre-weaning, at the maternal oral daily dose of 6.25 mg/kg. The latter appears to be a class effect of an opioid analgesic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Butyl&nbsp; hydroxytoluene&nbsp; E321,&nbsp; Cellulose&nbsp; acetate,&nbsp; Glycerol&nbsp; triacetate,&nbsp; Iron&nbsp; oxide&nbsp; black&nbsp; E172,</p><p>Hypromellose,&nbsp;&nbsp; Lactose,&nbsp;&nbsp; Macrogol,&nbsp;&nbsp; Magnesium&nbsp;&nbsp; stearate,&nbsp;&nbsp; Polyethylene&nbsp;&nbsp; oxide,&nbsp;&nbsp; Povidone,</p><p>Propylene glycol, Sodium chloride, Titanium dioxide E171</p><p>Ferric oxide red E172 (8 mg only)</p><p>Ferric oxide yellow E172 (16 mg and 32 mg only)</p><p>Indigo carmine lake E132 (64 mg only)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                See expiry date on the outer pack
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See outer carton.</p><p>Keep out of reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/Aclar aluminum blisters.</p><p>Pack sizes of 7, 10, 14, 20, 28, 30, 35, 40, 50, 56, 60, 100 tablets.</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Instructions for Disposal</p><p>Any&nbsp; unused&nbsp; product&nbsp; or&nbsp; waste&nbsp; material&nbsp; should&nbsp; be&nbsp; disposed&nbsp; of&nbsp; in&nbsp; accordance&nbsp; with&nbsp; local requirements.</p><p>&nbsp;</p><p>National Pharmacovigilance &amp; Drug Safety Centre (NPC) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong>Fax: +966-11-205-7662 <strong>&nbsp;</strong>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong></p><p>Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                See outer carton. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 January 2013 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>